MedTrace Logo

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

NCT02140151 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2022-08-25

No results posted yet for this study

Summary

This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab 0.5mg

Sponsors & Collaborators

  • Southern California Desert Retina Consultants, MC

    lead OTHER

Principal Investigators

  • Maziar Lalezary, MD · Southern California Desert Retina Consultants

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-17
Primary Completion
2020-07-09
Completion
2020-07-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02140151 on ClinicalTrials.gov